Peptide Therapy: What Clinics Offer, Legal Status and Cost

Med spas and wellness clinics use "peptide therapy" as an umbrella term for injections, capsules and creams organized around peptides.

Peptides are the class of molecule that approved drugs such as semaglutide and tirzepatide belong to, so the word itself covers both well-studied medicines and substances for which we found no FDA approval.

Under that one label, clinics sell two very different things.

The first is an approved peptide drug, prescribed for the narrow condition its label names.

Tesamorelin (Egrifta WR) is approved to reduce excess abdominal fat in adults with HIV-associated lipodystrophy, and its label says it is not for weight loss.

Bremelanotide (Vyleesi) is approved for acquired generalized hypoactive sexual desire disorder in premenopausal women.

The second is the usage behind the keyword itself: wellness peptides such as BPC-157, CJC-1295 and ipamorelin, which are not approved drugs in the sources we reviewed and whose legal footing turns on pharmacy compounding rules instead.

Compounding is the legal fault line for everything else on this page.

Federal law (FD&C Act section 503A) says a pharmacy or physician may compound a drug from a bulk drug substance — the base ingredient rather than an approved product — only if the substance has a USP or NF monograph, is a component of an FDA-approved drug, or appears on FDA's 503A bulks list.

Most "wellness" peptides meet none of those tests, so they can only be compounded under FDA's interim enforcement policy — and only if FDA has placed them in Category 1.

The clearest public record of what circulates under this label is FDA's own compounding paperwork, which names the substances nominated for use in compounding.

FDA's records name BPC-157, TB-500 (a thymosin beta-4 fragment), CJC-1295, AOD-9604, ipamorelin, cathelicidin LL-37, dihexa, emideltide (DSIP), epitalon, injectable GHK-Cu, KPV, PEG-MGF, melanotan II, MOTs-C, selank, semax and thymosin alpha-1.

Two more show up on the agency's significant-risk list: ibutamoren and kisspeptin-10, with GHRP-2 and GHRP-6 named for outsourcing facilities.

What each one is "for" is clinic marketing; in the sources we reviewed, none of BPC-157, TB-500, CJC-1295, ipamorelin, AOD-9604, MOTs-C, selank, semax or melanotan II appears as an FDA-approved drug for any use — a point the evidence section below takes up.

One use the official record does spell out is BPC-157, which FDA's advisory committee discussed in July 2026 as a nomination for ulcerative colitis.

We won't repeat clinics' claims for the rest without evidence behind them.

Some drip-menu ingredients overlap with this world: FDA's Category 1 list includes NAD, glutathione and vasoactive intestinal peptide, all used in med spa IV drips and shots — our IV therapy guide covers that side separately.

The approved contrast matters.

Semaglutide and tirzepatide are peptide drugs with FDA-approved versions, which our semaglutide and tirzepatide guides cover in depth.

Not every GLP-1 is a peptide, though: orforglipron (Foundayo), first approved in the US in 2026, is a non-peptide GLP-1.

Because most wellness peptides qualify for compounding under none of the three legal routes, everything turns on FDA's interim policy.

FDA sorts nominated bulk substances into three categories: Category 1 substances are under evaluation, and FDA does not intend to take action against a compounder using them if conditions are met; Category 2 substances carry significant safety risks, and FDA may take enforcement action; Category 3 substances were nominated without enough support and get no Category 1 protection at all.

The lists move, so the date matters.

On FDA's list updated May 14, 2026, the 503A Category 2 entries include cesium chloride, domperidone, germanium sesquioxide, ibutamoren mesylate, kisspeptin-10 and quinacrine for intrauterine use; for 503B outsourcing facilities, GHRP-2, GHRP-6, ipamorelin and ibutamoren are also Category 2.

The same May 2026 Category 1 list holds NAD, NADH, glutathione, methylcobalamin, alpha lipoic acid and vasoactive intestinal peptide — substances used in med spa IV drips and shots.

Effective April 22, 2026, FDA moved BPC-157, TB-500, CJC-1295, AOD-9604, ipamorelin (for 503A), cathelicidin LL-37, dihexa, DSIP, epitalon, injectable GHK-Cu, KPV, PEG-MGF, melanotan II, MOTs-C, selank, semax and thymosin alpha-1 off the Category 2 table into a "nominated but withdrawn" table, because the people who nominated them withdrew.

FDA's advisory committee then met on July 23–24, 2026 to discuss adding BPC-157, KPV, TB-500 and MOTs-C, and later DSIP, semax and epitalon, to the 503A bulks list — but committee recommendations are non-binding, and in our October 2026 review of the sources available to us, none of the withdrawn peptides had been added to the bulks list.

Two hard lines sit outside all the category shuffling.

FDA says retatrutide and cagrilintide cannot legally be used in compounding and are not in any FDA-approved drug, and that products sold "for research purposes" or "not for human consumption" containing semaglutide, tirzepatide, retatrutide, survodutide or mazdutide are illegal unapproved drugs.

Where compounded GLP-1s stand now is its own story — our guide to compounded GLP-1s covers it.

In the sources we reviewed, what FDA's documents record about the wellness peptides is safety concern, not demonstrated benefit.

The agency's main listed concern for compounded injectable peptides is immunogenicity — immune reactions driven by aggregation and peptide-related impurities — compounded by a lack of human safety data.

In its entry on BPC-157, FDA wrote that it has identified no, or only limited, safety-related information for the proposed routes of administration, and that the agency "lacks sufficient information to know whether the drug would cause harm when administered to humans." For the full safety picture, see is peptide therapy safe.

For a few named substances, FDA's posted summaries go further.

They associate CJC-1295 with serious adverse events including increased heart rate and systemic vasodilatory reactions, and melanotan II with published case reports of melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome and priapism.

Ibutamoren is listed as posing a potential risk of congestive heart failure, citing a hip-fracture trial stopped early over a heart-failure safety signal.

On whether the wellness peptides work for the uses clinics market, the honest answer is that we found no FDA approval to point to.

In the sources we reviewed, none of BPC-157, TB-500, CJC-1295, ipamorelin, AOD-9604, MOTs-C, selank, semax or melanotan II appears as a component of an FDA-approved drug for any use; our researchers flag that as an inference from absence rather than a drug-by-drug check of FDA's database, so read it as "no approval we could find," not proof.

The approved peptides show how narrow a real indication is: tesamorelin's label states it is not for weight loss, despite being approved to reduce abdominal fat in HIV-associated lipodystrophy.

We will not invent an average: our research turned up no reliable national price data for peptide programs, so treat any dollar figure you see for a wellness peptide program as one clinic's price until that clinic confirms what it includes.

Because clinics package protocols differently, the useful question is what a quoted price actually includes — the peptide itself, supplies, prescriber reviews, and any lab work — and what happens to the price when the dose or the program length changes.

One cost rule we can confirm comes from the IRS.

Publication 502 says vitamins, nutritional and herbal supplements are not deductible medical expenses — and so generally not HSA or FSA eligible — unless a medical practitioner recommends them as treatment for a specific condition diagnosed by a physician.

Ask before you assume a wellness peptide program can be paid from a flexible-spending account.

What the approved GLP-1 brands charge is its own topic — our guide to medical weight loss programs covers it, alongside the financing and membership questions to ask.

For the approved side, the answer is straightforward: Wegovy, Zepbound and Foundayo are prescription-only drugs, and FDA advises getting a prescription from a licensed prescriber and filling it at a state-licensed pharmacy.

The agency specifically flags sellers that skip the screening and the prescription.

For the compounded side, who may perform the injection is a state-by-state question.

AmSpa, the medical spa association, says injecting botulinum toxin is the practice of medicine because a prescription drug is being used to affect living tissue, and that such an injection must be done by a physician, an independent-practice NP, or another licensed professional acting within their scope, under rules that differ state by state.

AmSpa's explanation is written about botulinum toxin, and our sources include no state-by-state rulebook for compounded peptides — the supervision structures behind rules like these are what our guide to med spa laws by state explains.

A state can also draw its own line on peptides specifically.

In Mississippi, the State Board of Medical Licensure posts a joint statement that healthcare providers may not compound, administer or dispense non-FDA-approved, research-grade peptides to patients under any circumstances.

A state statement like that belongs to that state — it does not transfer anywhere else.

For the GLP-1 prescribing questions specifically, our guide to who can prescribe GLP-1s goes deeper.

Local directories can tell you which clinics offer peptide programs, but the safety questions are the same everywhere, and every one of them traces back to a fact above rather than to a sales page.

• Ask for the exact substance name in the vial, and whether it is an FDA-approved drug or a compounded bulk substance. Those are different products with different legal footing.
• Ask who wrote the prescription and which pharmacy compounds the product. FDA's advice for the approved GLP-1s — a licensed prescriber and a state-licensed pharmacy — is the clearest available benchmark.
• Treat "for research purposes only" or "not for human consumption" labels as the stop sign they are: FDA has issued warning letters to companies selling GLP-1-type peptides that way for human use and calls them unapproved drugs of unknown quality, and products marketed that way containing semaglutide, tirzepatide, retatrutide, survodutide or mazdutide are illegal unapproved drugs.
• Walk away from "the same as Wegovy" claims for compounded copies. FDA lists exactly that claim as a consumer red flag.
• Be skeptical of "FDA-approved" framing around Category 1 substances. Evaluation is not approval, and a clinic that blurs the line has told you something useful.

For the provider-side checks that apply to any treatment — medical directorship, who actually does the injecting, what a legitimate consultation looks like — our how to choose a med spa checklist walks through them in order.